Kara I Geren1, Frank Lovecchio2, Jason Knight2, Robert Fromm3, Eric Moore4, Cheri Tomlinson4, André Valdez5, Dan Hobohm6, J Stephan Stapczynski2. 1. Department of Emergency Medicine, Maricopa Integrated Health System, Phoenix, AZ. Electronic address: kara_geren@dmgaz.org. 2. Department of Emergency Medicine, Maricopa Integrated Health System, Phoenix, AZ. 3. Department of Internal Medicine, Maricopa Integrated Health System, Phoenix, AZ. 4. Department of Grants Administration, Maricopa Integrated Health System, Phoenix, AZ. 5. Department of Academic Research, Maricopa Integrated Health System, Phoenix, AZ. 6. Department of Pathology, Maricopa Integrated Health System, Phoenix, AZ.
Abstract
STUDY OBJECTIVE: Acute HIV infection is a clinical diagnosis aided by technology. Detecting the highly infectious acute stage of HIV infection is critical to reducing transmission and improving long-term outcomes. The Maricopa Integrated Health System implemented nontargeted, opt-out HIV screening with a fourth-generation antigen/antibody combination HIV assay test in our adult emergency department (ED) at Maricopa Medical Center to assess the prevalence of both acute and chronic unrecognized HIV. METHODS: Eligible patients aged 18 to 64 years were tested for HIV if they did not opt out and had blood drawn as part of their ED care. Patients were not eligible if they had a known HIV or AIDS diagnosis, exhibited altered mental status, were a current resident of a long-term psychiatric or correctional facility, or prompted a trauma activation. Reactive test results were delivered by a physician with the assistance of a linkage-to-care specialist. Specimens with a reactive fourth-generation assay result underwent confirmatory testing. RESULTS: From July 11, 2011, through January 5, 2014, 27,952 HIV screenings were performed for 22,468 patients tested for HIV; 78 (0.28%) had new HIV diagnoses. Of those, 18 (23% of all new diagnoses) were acute HIV infections, and 22 patients (28%) had a CD4 count of less than 200 cells/mL, or an opportunistic infection. CONCLUSION: HIV testing with a fourth-generation antigen/antibody laboratory test producing rapid results is feasible in an ED. Unexpectedly, nearly one fourth of patients with undiagnosed HIV had acute infections, which would have been more difficult to detect with previous testing technology.
STUDY OBJECTIVE:Acute HIV infection is a clinical diagnosis aided by technology. Detecting the highly infectious acute stage of HIV infection is critical to reducing transmission and improving long-term outcomes. The Maricopa Integrated Health System implemented nontargeted, opt-out HIV screening with a fourth-generation antigen/antibody combination HIV assay test in our adult emergency department (ED) at Maricopa Medical Center to assess the prevalence of both acute and chronic unrecognized HIV. METHODS: Eligible patients aged 18 to 64 years were tested for HIV if they did not opt out and had blood drawn as part of their ED care. Patients were not eligible if they had a known HIV or AIDS diagnosis, exhibited altered mental status, were a current resident of a long-term psychiatric or correctional facility, or prompted a trauma activation. Reactive test results were delivered by a physician with the assistance of a linkage-to-care specialist. Specimens with a reactive fourth-generation assay result underwent confirmatory testing. RESULTS: From July 11, 2011, through January 5, 2014, 27,952 HIV screenings were performed for 22,468 patients tested for HIV; 78 (0.28%) had new HIV diagnoses. Of those, 18 (23% of all new diagnoses) were acute HIV infections, and 22 patients (28%) had a CD4 count of less than 200 cells/mL, or an opportunistic infection. CONCLUSION: HIV testing with a fourth-generation antigen/antibody laboratory test producing rapid results is feasible in an ED. Unexpectedly, nearly one fourth of patients with undiagnosed HIV had acute infections, which would have been more difficult to detect with previous testing technology.
Authors: Patrick S Sullivan; Michael S Lyons; Maggie Czarnogorski; Bernard M Branson Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Danielle Signer; Stephen Peterson; Yu-Hsiang Hsieh; Somiya Haider; Mustapha Saheed; Paula Neira; Cassie Wicken; Richard E Rothman Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Bernard M Branson; Pollyanna R Chavez; Brett Hanscom; Elizabeth Greene; Laura McKinstry; Kate Buchacz; Geetha Beauchamp; Theresa Gamble; Barry S Zingman; Edward Telzak; Tammey Naab; Lisa Fitzpatrick; Wafaa M El-Sadr Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: Jason S Haukoos; Michael S Lyons; Douglas A E White; Yu-Hsiang Hsieh; Richard E Rothman Journal: Ann Emerg Med Date: 2014-08-13 Impact factor: 5.721
Authors: Lucia V Torian; Uriel R Felsen; Qiang Xia; Fabienne Laraque; Eric J Rude; Herbert Rose; Adam Cole; Angelica Bocour; Gary J Williams; Robert F Bridgforth; Lisa A Forgione; Howard Doo; Sarah L Braunstein; Demetre C Daskalakis; Barry S Zingman Journal: Am J Public Health Date: 2018-03-22 Impact factor: 9.308
Authors: Kara G Marson; Robert Marlin; Phong Pham; Stephanie E Cohen; Diane Jones; Marguerite Roemer; Philip J Peters; Barbara Haller; Christopher D Pilcher Journal: J Clin Virol Date: 2017-04-07 Impact factor: 3.168
Authors: Yu-Hsiang Hsieh; Gabor D Kelen; Kaylin J Beck; Chadd K Kraus; Judy B Shahan; Oliver B Laeyendecker; Thomas C Quinn; Richard E Rothman Journal: Am J Emerg Med Date: 2015-10-09 Impact factor: 2.469
Authors: Douglas A E White; Erik S Anderson; Sarah K Pfeil; Laura J Deering; Tamara Todorovic; Tarak K Trivedi Journal: PLoS One Date: 2016-10-19 Impact factor: 3.240
Authors: Sarah E Rutstein; Jintanat Ananworanich; Sarah Fidler; Cheryl Johnson; Eduard J Sanders; Omar Sued; Asier Saez-Cirion; Christopher D Pilcher; Christophe Fraser; Myron S Cohen; Marco Vitoria; Meg Doherty; Joseph D Tucker Journal: J Int AIDS Soc Date: 2017-06-28 Impact factor: 5.396